Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Jennifer Huang, Laura Samples, Ted Gooley, Margo Fredericks, Stephanie Louie, Grace Bishop, Christine Crider, Mehrdad Azar, Neena Kennedy, Mengyang Di, Stephen Smith, Brian Till, Ajay Gopal, Ryan Lynch, Chaitra Ujjani, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2025-2136

Published: 2025

Journal Articles

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Xiancheng Wu, Solomon Graf, Ryan Lynch, Chaitra Ujjani, Ted Gooley, Jenna Voutsinas, Heather Rasmussen, Wendy Felder, Kristi Matsumura, Andrew Cowan, Stephen Smith, Mazyar Shadman, Edus Warren, Jonathan Fromm, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5355.

https://doi.org/10.1182/blood-2025-5355

Published: 2025

Journal Articles

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 402.

https://doi.org/10.1182/blood-2025-402

Published: 2025

Journal Articles

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

Blood (2025) 146 (Supplement 1): 401.

https://doi.org/10.1182/blood-2025-401

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Ryan Lynch, Christina Poh, Mazyar Shadman, Brian Till, Mengyang Di, Chaitra Ujjani, Vikram Raghunathan, Stephen Smith, David Maloney, Daria Gausman, Heather Rasmussen, David Russler-Germain, Todd Fehniger, David Kurtz, Ash Alizadeh, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2025-3591

Published: 2025

Journal Articles

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Blood (2025) 146 (Supplement 1): 4499.

https://doi.org/10.1182/blood-2025-4499

Published: 2025

Journal Articles

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

Mengyang Di, Qian Wu, Ryan Lynch, Stephen Smith, Mazyar Shadman, Paul Martin, Brian Till, Neena Kennedy, Chaitra Ujjani, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2025-5394

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Real-world barriers to treatment access in T-cell lymphoma

Bryce Bowler, Jenna Voutsinas, Qian Wu, Maya Krishnan, Dhruv Mistry, Grace Sun, Mazyar Shadman, Brian Till, Ryan Lynch, Vikram Raghunathan, Chaitra Ujjani, Stephen Smith, Mengyang Di, Paul Martin, Ajay Gopal, Christina Poh

Blood (2025) 146 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2025-4491

Published: 2025

Journal Articles

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Stephen Smith, Suchitra Sundaram, Sharmila Giri, Andy Ness, Yucai Wang, Yifan Pang, Ajay Gopal, Emily Tatoian, Trenton Grossfeld, Ryan Lynch, Edus Warren, Grzegorz Nowakowski, Steven Park

Blood (2025) 146 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2025-3575

Published: 2025

Journal Articles

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Blood (2018) 132 (12): 1225–1240.

https://doi.org/10.1182/blood-2018-04-843771

Published: 2018

Includes: Supplemental data

Journal Articles

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Allison M. Winter, Daniel J. Landsburg, Anthony R. Mato, Krista Isaac, Francisco J. Hernandez-Ilizaliturri, Nishitha Reddy, Stephen Smith, Mazyar Shadman, Mitchell R. Smith, Paolo Caimi, Deepa Jagadeesh, Brian T. Hill

Blood (2017) 130 (14): 1676–1679.

https://doi.org/10.1182/blood-2017-05-786988

Published: 2017

Journal Articles

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R. Flowers, Franck Morschhauser, Graham P. Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C. Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M. Beaupre, Robert Chen

Blood (2017) 129 (16): 2224–2232.

https://doi.org/10.1182/blood-2016-10-747345

Published: 2017

Includes: Supplemental data

Journal Articles

Characterisation of E. coli Lipopolysaccharide Adherence to Platelet Receptors

Dearbhla Lenehan, BSc, Alyson Murray, BSc PhD, Stephen Smith, BA PhD, Bernt Eric Uhlin, Jennifer Mitchell, BA PhD

Blood (2016) 128 (22): 4906.

https://doi.org/10.1182/blood.V128.22.4906.4906

Published: 2016

Journal Articles

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Ariela Noy, MD PhD, Sven de Vos, MD PhD, Catherine Thieblemont, MD PhD, Peter Martin, MD, Christopher Flowers, MDMS, Franck Morschhauser, Graham P. Collins, MD PhD, Shuo Ma, Morton Coleman, MD, Shachar Peles, MD, Stephen Smith, MD, Alina Smith, Brian Munneke, PhD, Isaiah Dimery, MD, Darrin Beaupre, MD PhD, Robert W Chen, MD

Blood (2016) 128 (22): 1213.

https://doi.org/10.1182/blood.V128.22.1213.1213

Published: 2016

Journal Articles

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Allison Marie Winter, MD, Daniel J. Landsburg, MD, Francisco J. Hernandez-Ilizaliturri, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Smith, MD, Mazyar Shadman, Paolo Caimi, MD, Deepa Jagadeesh, MD MPH, Mitchell R. Smith, Brian T. Hill, MD PhD

Blood (2016) 128 (22): 1115.

https://doi.org/10.1182/blood.V128.22.1115.1115

Published: 2016

Journal Articles

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Sandra Kanan, NP, RN, MSN, Ajay K Gopal, MD, Ryan D Cassaday, MD, Andrei R. Shustov, MD, Brian G. Till, MD, Andrew J. Cowan, MD, Mazyar Shadman, MD MPH, Warren Houston, MD PhD, Melinda Tran, Pharm.D, Oliver Press, Stephen Smith, MD

Blood (2016) 128 (22): 3577.

https://doi.org/10.1182/blood.V128.22.3577.3577

Published: 2016

Journal Articles

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Stephen Smith, Robert Dean, Matt E Kalaycio, MD, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward Copelan, John William Sweetenham

Blood (2009) 114 (22): 3325.

https://doi.org/10.1182/blood.V114.22.3325.3325

Published: 2009

Journal Articles

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Alison J. Moskowitz, MD, John Sweetenham, MD, Brian J. Bolwell, MD, Jocelyn C Maragulia, Jill M Vanak, ACNP, Craig H Moskowitz, MD, Stephen Smith, MD

Blood (2009) 114 (22): 3413.

https://doi.org/10.1182/blood.V114.22.3413.3413

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL

Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Real-world barriers to treatment access in T-cell lymphoma

Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Characterisation of E. coli Lipopolysaccharide Adherence to Platelet Receptors

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only